World Autism Awareness Day 2027: SDG Resources' Deep Dive

On April 2, 2027, the global community will come together to observe World Autism Awareness Day 2027. This occasion, significantly elevated by the commitment of SDG Resources, showcases the powerful intersection of Sustainable Development Goals (SDGs) and autism advocacy.

Introduction: The Importance of April 2

This book chapter advances SDG3 Good Health and Wellbeing and SDG 10 Reducing Inequalities by reviewing a pilot rehabilitation program for children with a combination of intellectual/autism spectrum disorder and motor disorders.

This book chapter advances SDG3 Good Health and Wellbeing and SDG10 Reducing Inequalities by reviewing the outcome of children and babies with ASD in later life, focusing on new biomedical research and also state-of-the-art techniques that are multidisciplinary between engineering and clinical research.

This book chapter advances SDGs 3 and 17 by reviewing a new promising neuroprotective approach to treating AZ, Tau-based therapies including tau-kinase inhibitors to acetylation inhibitors, microtubule stabilizers, aggregation inhibitors, monoclonal anti-tau antibodies or active tau vaccines. Special emphasis has been placed on the most promising therapeutic agents that have reached clinical trials.

Objective imaging-based biomarker discovery for psychiatric conditions is critical for accurate diagnosis and treatment. Using a machine learning framework, this work investigated the utility of brain's functional network topology (complex network features) extracted from functional magnetic resonance imaging (fMRI) functional connectivity (FC) as viable biomarker of autism spectrum disorder (ASD). To this end, we utilized resting-state fMRI data from the publicly available ABIDE dataset consisting of 432 ASD patients and 556 matched healthy controls.

Recent progress in the genomics of non-syndromic autism spectrum disorder (nsASD) highlights rare, large-effect, germline, heterozygous de novo coding mutations. This distinguishes nsASD from later-onset psychiatric disorders where gene discovery efforts have predominantly yielded common alleles of small effect. These differences point to distinctive opportunities for clarifying the neurobiology of nsASD and developing novel treatments.

Altered synaptic structure and function is a major hallmark of fragile X syndrome (FXS), autism spectrum disorders (ASDs), and other intellectual disabilities (IDs), which are therefore classified as synaptopathies. FXS and ASDs, while clinically and genetically distinct, share significant comorbidity, suggesting that there may be a common molecular and/or cellular basis, presumably at the synapse.